Primera Specialty Infusion Highlights New Advances in IBD Care with Omvoh®

At Primera Specialty Infusion, we believe patients deserve access to innovative treatments close to home, with compassionate support every step of the way.

One of the newest advancements in inflammatory bowel disease (IBD) care is Omvoh, a biologic therapy approved for adults with moderately to severely active ulcerative colitis and Crohn’s disease. Omvoh works by targeting the IL-23 pathway, which plays a major role in inflammation associated with IBD.

The FDA first approved Omvoh for ulcerative colitis in 2023, followed by approval for Crohn’s disease in 2025, expanding treatment options for patients living with chronic digestive conditions.

Omvoh also offers a treatment approach designed with both effectiveness and convenience in mind. Therapy begins with IV loading doses administered in a monitored infusion setting, followed by subcutaneous maintenance injections patients can continue more conveniently at home. This hybrid approach allows patients to receive the benefits of guided infusion support initially while transitioning to a more flexible long-term maintenance routine.

One feature generating excitement among both providers and patients is Omvoh’s flexibility for real-world living. The medication can remain unrefrigerated for up to two weeks, which is especially valuable here in Florida during hurricane season, unexpected power outages, summer travel, and evacuation situations. For many patients managing chronic conditions, that added peace of mind can make a meaningful difference in maintaining treatment consistency and reducing stress surrounding medication storage.

For individuals battling IBD, symptoms like abdominal pain, urgency, fatigue, and inflammation can impact every part of daily life. Newer biologic therapies such as Omvoh are helping create more opportunities for symptom control, remission, and improved quality of life.

At Primera Specialty Infusion, our team supports patients through every stage of the infusion journey, including insurance coordination, prior authorizations, financial assistance navigation, and comfortable outpatient infusion care designed around the patient experience.

As specialty therapies continue evolving, community-based infusion centers play an important role in improving access to advanced care while helping patients remain connected to the communities they call home.

“We are passionate about helping patients access specialty medications in a setting that feels personal, supportive, and centered around their quality of life,” said Amy Sue Harper, CEO & Founder of Primera Specialty Infusion.

To learn more about Primera Specialty Infusion and the specialty therapies we support, visit www.PrimeraSpecialty.com.